JPMorgan Chase & Co. restated their overweight rating on shares of Hikma Pharmaceuticals Plc (LON:HIK) in a research report released on Thursday, StockTargetPrices.com reports.
HIK has been the subject of several other research reports. Jefferies Group cut their price objective on Hikma Pharmaceuticals Plc from GBX 2,500 ($31.23) to GBX 2,000 ($24.99) and set a buy rating for the company in a report on Friday, November 11th. Numis Securities Ltd reaffirmed a hold rating and issued a GBX 2,660 ($33.23) price objective on shares of Hikma Pharmaceuticals Plc in a report on Wednesday, August 24th. Citigroup Inc. reaffirmed a neutral rating on shares of Hikma Pharmaceuticals Plc in a report on Wednesday. Barclays PLC reaffirmed an overweight rating and issued a GBX 2,900 ($36.23) price objective on shares of Hikma Pharmaceuticals Plc in a report on Friday, September 9th. Finally, Morgan Stanley began coverage on Hikma Pharmaceuticals Plc in a report on Thursday, July 21st. They issued an equal weight rating and a GBX 2,700 ($33.73) price objective for the company. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The company has a consensus rating of Buy and an average price target of GBX 2,337.40 ($29.20).
Shares of Hikma Pharmaceuticals Plc (LON:HIK) traded down 0.36% during mid-day trading on Thursday, reaching GBX 1658.00. The company had a trading volume of 364,034 shares. The stock’s market capitalization is GBX 3.75 billion. Hikma Pharmaceuticals Plc has a one year low of GBX 1,575.00 and a one year high of GBX 2,703.00. The firm has a 50 day moving average of GBX 1,869.22 and a 200-day moving average of GBX 2,194.52.
In other Hikma Pharmaceuticals Plc news, insider Darwazah,Said acquired 200,000 shares of the stock in a transaction dated Friday, August 26th. The shares were acquired at an average cost of GBX 2,160 ($26.99) per share, for a total transaction of £4,320,000 ($5,397,301.35). Also, insider Al-Husry,Ali acquired 140,000 shares of the stock in a transaction dated Wednesday, August 31st. The stock was acquired at an average price of GBX 2,150 ($26.86) per share, for a total transaction of £3,010,000 ($3,760,619.69).
Hikma Pharmaceuticals Plc Company Profile
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company develops, manufactures and markets a range of branded and non-branded generic pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms, across the United States, the Middle East and North Africa (MENA) region and Europe.
Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with MarketBeat.com's FREE daily email newsletter.